Table 1:
Summary of surgical outcomes for microsurgical and endoscopic case series.
| Microsurgical Case Series | ||||||||
|---|---|---|---|---|---|---|---|---|
| Author | Year | Patients, n | Initial Remission, n | Patients with f/u, n |
f/u, mo | Relapse, n |
Remission at last f/u, n |
Remission Criteria |
| Fathalla H et al | 2015 | 23 | 8 | 23 | 56.6 | 0 | - | 2010 |
| Sarkar S et al | 2014 | 47 | 17 | 47 | 22.38 | 0 | - | 2010 |
| Nishioka H et al | 2014 | 150 | 127 | 150 | 22 | 0 | 149 | 2010 |
| Sun H et al | 2014 | 59 | 26 | 59 | 13.4 | 0 | 31 | 2010 |
| Starke RM et al | 2013 | 41 | 28 | 41 | 18.4 | 0 | 28 | 2010 |
| Li ZQ et al | 2012 | 52 | 16 | 49 | 3 | 0 | 16 | 2000 |
| Krzentowaka-Korek A et al | 2011 | 85 | 32 | - | - | 0 | - | 2000 |
| Shen M et al | 2010 | 39 | 7 | 39 | - | 0 | 8 | 2000 |
| Abassioun K et al | 2006 | 151 | 101 | 108 | - | 2 | 99 | Random GH ≤ 10 ng/mL |
| Ertruk E et al | 2005 | 30 | 10 | 30 | 42 | 0 | - | Basal or OGTT GH ≤ 2 ng/mL |
| Nomikos P et al | 2005 | 506 | 290 | 506 | 146 | 2 | 288 | 2000 |
| Kurosaki M et al | 2003 | 22 | 13 | 22 | - | 0 | 13 | Normalized IGF-1, OGTT GH < 1 ng/mL, basal GH < 2.5 ng/mL |
| Beauregard C et al | 2003 | 103 | 56 | 95 | - | 4 | 57 | 2000 |
| De P et al | 2003 | 90 | 57 | 90 | 130.8 | 0 | 57 | 2000 |
| Krieger MD et al | 2003 | 205 | 116 | 181 | 60 | 1 | 116 | Normalized IGF-1, basal GH < 2 ng/mL |
| Kreutzer J et al | 2001 | 57 | 40 | 57 | 37.7 | 1 | 41 | 2000 |
| Biermasz NR et al | 2000 | 59 | 36 | 59 | 192 | 5 | 58 | 2000 |
| Absoch A et al | 1998 | 254 | 193 | 172 | - | 9 | 150 | Basal GH ≤ 5 ng/mL |
| Freda PU et al | 1998 | 115 | 70 | 99 | 64.8 | 6 | 82 | Normalized IGF-1 or basal/suppressed GH of ≤ 2 ng/mL |
| Yamada S et al | 1997 | 44 | 25 | 39 | 81.6 | 0 | 34 | Normalized IGF-1, basal GH ≤ 3 ng/mL, OGTT GH ≤ 1ng/mL, TRH/ GnRH GH < 10ng/mL |
| Sheaves R et al | 1996 | 100 | 42 | 32 | 45.6 | 1 | 31 | Basal GH ≤ 5 ng/mL |
| Osman IA et al | 1994 | 79 | 32 | 66 | 85.5 | - | 35 | Basal GH ≤ 5 mU/L and OGTT GH ≤ 2 mU/L |
| Tindall GT et al | 1993 | 103 | 85 | 88 | 102 | 0 | 85 | Basal GH ≤ 5 ng/mL, SM-C < 2.2 U/mL |
| Buchfelder M et al | 1991 | 61 | 43 | 61 | 72 | 6 | 39 | Basal GH ≤ 5ng/mL and OGTT GH ≤ 2 ng/mL |
| Losa M et al | 1989 | 29 | 16 | 25 | - | 0 | 12 | OGTT GH ≤ 1 ng/mL and normalized SM-C |
| Fahlbusch R et al | 1988 | 42 | 24 | - | - | - | - | Basal GH ≤ 5 ng/mL |
| van’t Verlaat J. et al | 1988 | 25 | 14 | 25 | 42 | 0 | 14 | Basal GH ≤ 5 mU/L; OGTT GH ≤ 4 mU/L; disappearance of TRH responsiveness if present pre-op |
| Ross DA et al | 1988 | 214 | 117 | 174 | 76 | 5 | 131 | Basal GH ≤ 5 ng/mL |
| Arafah BM et al | 1987 | 43 | 21 | 43 | - | 0 | 21 | Basal GH ≤ 5 ng/mL and normal GH dynamics |
| Karashima T et al | 1986 | 44 | 15 | - | - | - | - | Fasting GH ≤ 5 ng/mL and no response to TRH, LHRH, and/or bromocriptine |
| Roelfesma F et al | 1985 | 60 | 37 | 60 | 39.6 | - | 48 | Basal GH ≤ 5 mU/L |
| Serri O et al | 1985 | 25 | 21 | 25 | 82.8 | 3 | 18 | Basal GH ≤ 5 ng/mL and OGTT GH ≤ 2.5 ng/mL |
| Grisoli F et al | 1985 | 100 | 60 | 100 | - | 6 | 56 | Basal GH ≤ 5 ng/mL |
| Bynke O et al | 1983 | 14 | 10 | 14 | 27 | 1 | 11 | Basal GH ≤ 5 ng/mL |
| Arafah BU et al | 1980 | 25 | 11 | 25 | - | 0 | 11 | Basal GH < 5ng/mL and normal GH dynamics |
| Tucker HS et al | 1980 | 32 | 24 | 32 | 48 | 0 | 24 | Basal GH ≤ 5 ng/mL |
| Laws ER Jr et al | 1979 | 82 | 34 | 80 | 19 | 1 | 50 | Basal GH ≤ 10 ng/mL |
| Leavens ME et al | 1977 | 16 | 10 | 16 | 24 | 0 | 12 | Basal HGH ≤ 10 ng/mL and normal HGH levels after TRH stimulation |
| Giovanelli MA et al | 1976 | 29 | 10 | 29 | - | 0 | 17 | Basal GH ≤ 10 ng/mL |
| Total | 3255 | 1894 | 2761 | 59.8 | 53 | 1842 | ||
| Endoscopic Case series | ||||||||
| Netuka D et al | 2016 | 105 | 64 | 105 | 35 | 1 | - | 2010 |
| Halioglu O et al | 2016 | 103 | 53 | 103 | 38 | 30 | 77 | 2000 |
| Fathalla H et al | 2015 | 42 | 19 | 42 | 56.6 | 0 | - | 2010 |
| Sarkar S et al | 2014 | 66 | 19 | 66 | 22.4 | 0 | - | 2010 |
| Yildirum A et al | 2014 | 56 | 37 | 56 | 18 | 0 | 53 | 2010 |
| Paluzzi A et al | 2014 | 49 | 25 | 49 | 37.3 | 0 | 34 | 2010 |
| Zhou T et al | 2014 | 133 | 88 | 114 | - | 0 | 107 | 2000 |
| Hazer DB et al | 2013 | 214 | 126 | 214 | 33.16 | 0 | 134 | 2010 |
| Starke RM et al | 2013 | 72 | 51 | 72 | 18.4 | 0 | 51 | 2010 |
| van Bunderen CC | 2013 | 30 | 9 | 28 | 13.2 | 1 | - | 2000 |
| Wang YY et al | 2012 | 43 | 29 | 41 | 34 | 0 | 29 | 2010 |
| Dusek T et al | 2011 | 49 | 29 | 49 | 57.12 | 0 | 36 | 2000 |
| Wagenmakers MA et al | 2011 | 40 | 20 | 40 | 56 | 2 | 19 | IGF-1 normal for age and sex, OGTT GH < 2 mU/l |
| Gondim JA et al | 2010 | 67 | 50 | 67 | 24 | 0 | 54 | 2000 |
| Hofstetter CP et al | 2010 | 24 | 9 | 24 | 23.2 | 0 | 11 | 2010 |
| Campbell PG et al | 2010 | 27 | 15 | 26 | 24.5 | 0 | 15 | IGF-1 normal for age/sex, OGTT GH < 1ng/mL, random GH < 2.5 ng/mL |
| Total | 1120 | 643 | 1096 | 62.7 | 34 | 620 | ||
Abbreviations: GH = growth hormone; OGTT = oral glucose tolerance test; IGF-1 = insulin-like growth factor 1; GnRH = gondatropin releasing hormone; SM-C = somatomedin C, TRH = thyrotropin releasing hormone, LHRH = lutenizing hormone releasing hormone, n = number, mo = month, f/u = follow up.